SAT-355 Thyrotoxicosis Associated with Leukopenia in Graves' Disease: A Case Report and Review of Medical Management

Abstract Disclosure: C. Makhija: None. M. Bhalla: None. S.S. Thangwaritorn: None. Leukopenia is characterized by a low white blood cell count (WBC) and, is an uncommon manifestation of hyperthyroidism associated with Graves’ disease, affecting approximately 10% of patients. The dilemma arises in choosing antithyroid drugs for treatment, considering their rare adverse effect of agranulocytosis. We present the case of a 35-year-old female hospitalized for sinus tachycardia, leukopenia, and anemia, and diagnosed with new-onset hyperthyroidism. Blood work at the hospital revealed elevated thyroid stimulating immunoglobulin of 2.72 IU/L (TSI range 0.54 IU/L or less), TSH of <0.001 (normal 0.4 - 4mlU/L), elevated free T3 at 7.9 pg/mL (normal 1.3 - 4.5pg/mL), and elevated free T4 at 3.36 ng/dL (normal 0.8 - 1.8 ng/dL), accompanied by low white blood cell of 2.9 K/mm³ (normal 4500-11,000/mm³), absolute neutrophil count 1,768/µL (normal 1,500 - 7,800/µL) and low hemoglobin of 7.6 gm/dL (normal female 12.1 -15.1 gm/dL). She was discharged with β-blockers and due to antithyroid drug contraindication, she was advised to pursue thyroidectomy. The patient desired medical management and was treated with low-dose methimazole at the endocrine outpatient visit with us. Hematology evaluation ruled out alternative causes of leukopenia. Gradual improvement ensued with methimazole therapy, improving thyroid hormone levels, and normalization of white blood cell count, and hemoglobin. This case challenges the perception of mild-moderate leukopenia as an absolute antithyroid drug contraindication, highlighting the potential for treating hyperthyroidism due to Graves’ disease with antithyroid agent to normalize white blood cell counts. Awareness of this rare complication and consideration of antithyroid drugs in selected cases can offer a viable therapeutic option, providing valuable insights for clinicians managing hyperthyroidism complicated by leukopenia. Presentation: Saturday, July 12, 2025

Institutions

Publication Details

Journal
Journal of the Endocrine Society
Published
2025-10-01
DOI
https://doi.org/10.1210/jendso/bvaf149.2273
Primary Topic
Blood disorders and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

SAT-355 Thyrotoxicosis Associated with Leukopenia in Graves' Disease: A Case Report and Review of Medical Management

Journal of the Endocrine Society
Blood disorders and treatments
article

SAT-355 Thyrotoxicosis Associated with Leukopenia in Graves' Disease: A Case Report and Review of Medical Management

article en

Abstract

Abstract Disclosure: C. Makhija: None. M. Bhalla: None. S.S. Thangwaritorn: None. Leukopenia is characterized by a low white blood cell count (WBC) and, is an uncommon manifestation of hyperthyroidism associated with Graves’ disease, affecting approximately 10% of patients. The dilemma arises in choosing antithyroid drugs for treatment, considering their rare adverse effect of agranulocytosis. We present the case of a 35-year-old female hospitalized for sinus tachycardia, leukopenia, and anemia, and diagnosed with new-onset hyperthyroidism. Blood work at the hospital revealed elevated thyroid stimulating immunoglobulin of 2.72 IU/L (TSI range 0.54 IU/L or less), TSH of <0.001 (normal 0.4 - 4mlU/L), elevated free T3 at 7.9 pg/mL (normal 1.3 - 4.5pg/mL), and elevated free T4 at 3.36 ng/dL (normal 0.8 - 1.8 ng/dL), accompanied by low white blood cell of 2.9 K/mm³ (normal 4500-11,000/mm³), absolute neutrophil count 1,768/µL (normal 1,500 - 7,800/µL) and low hemoglobin of 7.6 gm/dL (normal female 12.1 -15.1 gm/dL). She was discharged with β-blockers and due to antithyroid drug contraindication, she was advised to pursue thyroidectomy. The patient desired medical management and was treated with low-dose methimazole at the endocrine outpatient visit with us. Hematology evaluation ruled out alternative causes of leukopenia. Gradual improvement ensued with methimazole therapy, improving thyroid hormone levels, and normalization of white blood cell count, and hemoglobin. This case challenges the perception of mild-moderate leukopenia as an absolute antithyroid drug contraindication, highlighting the potential for treating hyperthyroidism due to Graves’ disease with antithyroid agent to normalize white blood cell counts. Awareness of this rare complication and consideration of antithyroid drugs in selected cases can offer a viable therapeutic option, providing valuable insights for clinicians managing hyperthyroidism complicated by leukopenia. Presentation: Saturday, July 12, 2025

Journal of the Endocrine SocietyVol. 9(Supplement_1)
Clovis Community College (US), Fresno City College (US), Clovis Oncology (United States) (US), California State University, Fresno (US)
Good health and well-being
Openalex Percentile: Top 33%
Blood disorders and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.